Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | MAOB | P27338 | 11/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68892 | 0.86 | MAPT (0.69) | KDM4EALDH1A1MAOBMAPTNPC1 | |
| SCHEMBL6385719 | 0.83 | ALDH1A1 (0.69) | KDM4EALDH1A1MAOBMAPTNPC1 | |
| SCHEMBL29640611 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAOBMAPTHTR2C | |
| SCHEMBL1569957 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAOBMAPTNPC1 | |
| SCHEMBL29922134 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAOBMAPTNPC1 | |
| SCHEMBL6552997 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAOBMAPTHTR2C | |
| SCHEMBL4727223 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAOBMAPTNPC1 | |
| SCHEMBL2319848 | 0.81 | ALDH1A1 (0.67) | KDM4EALDH1A1MAOBMAPTNPC1 | |
| SCHEMBL1983108 | 0.81 | ALDH1A1 (1.00) | KDM4EALDH1A1MAOBMAPTHTR2C | |
| SCHEMBL30132496 | 0.81 | ALDH1A1 (1.00) | KDM4EALDH1A1MAOBMAPTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | SPARK BIOPHARMA, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023277656-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | (주)스파크바이오파마 | 2023-01-05 | — | — | WO | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015124868-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2015-08-27 | — | — | WO | disclosed |
| EP-2154213-A1 | Ink-jet ink composition, and ink-jet recording method | Fujifilm Corporation (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008035356-A2 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | MYD88, MYADM, CD14 | KDM4E 588/4885ALDH1A1 2146/4885MAOB 3668/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | KDM4E 517/4885ALDH1A1 600/4885MAOB 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.